Convenient Multiple-Dose Vial 30 mL vial allows flexible, cost-effective dosing for patients and clinics, with each mL delivering 1,000 mcg of high-potency hydroxocobalamin
Both medications affect metabolic pathways, making provider oversight essential before combining them
Hirota, 2021)
Bielinski SJ, Yanes Cardozo LL, Takahashi PY, Larson NB, Castillo A, Podwika A, De Filippis E, Hernandez V, Mahajan GJ, Gonzalez C, Shubhangi, Decker PA, Killian JM, Olson JE, St Sauver JL, Shah P, Vella A, Ryu E, Liu H, Marshall GD, Cerhan JR, Singh D, Summers RL
If approved, it will be the first GLP-1 to treat MASH, and an FDA decision is anticipated by the third quarter of 2025